Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Molbio Diagnostics

Explore full profile

Enabling better medicine through precise, rapid, cost-effective molecular diagnosis at the Point of Care

Mormugao, IndiaFounded 2000Health Tech & Medtech
Valuation $1–2.5B Last recorded · 2022
Revenue $100–500M Latest reported FY
Headcount 500–1k Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Molbio Diagnostics and the history behind them.

About Molbio Diagnostics

Molbio Diagnostics specializes in developing and manufacturing advanced chip-based Real Time Polymerase Chain Reaction (PCR) diagnostic tests. The company serves healthcare providers, hospitals, and diagnostic labs, offering solutions for rapid and accurate detection of infectious diseases such as tuberculosis, COVID-19, H1N1, HPV, Salmonella, and HIV. Operating in the global healthcare diagnostics market, Molbio's business model revolves around the sale of disposable, room temperature stable diagnostic chips and automated PCR analyzers. Revenue is generated through the direct sale of these diagnostic products and associated consumables. The company's flagship product line, TrueNat, is endorsed by the World Health Organization and validated by the Indian Council of Medical Research, highlighting its reliability and effectiveness. Molbio's solutions are designed to be user-friendly, enabling quick and precise diagnostics even in resource-limited settings, thereby improving patient outcomes and aiding in the control of infectious diseases.

Source: Dealroom company data

At a glance

Founded
2000
Headquarters
Mormugao, India
Sector
Health Tech & Medtech
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom
News
News Molbio swings to Rs 52.7 crore Q1 profit after Rs 940 crore IPO Sep 7, 2026 News Molbio Diagnostics raises Rs 281 crore from anchor investors ahead of IPO Aug 8, 2026

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Motilal Oswal Private Wealth Management
  • Temasek

Talent

Book a demo to see the people
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
15 countries with
team presence
🇮🇳 India94.7%
🇬🇧 United Kingdom0.5%
🇺🇸 United States0.5%
🇿🇦 South Africa0.5%
🇪🇹 Ethiopia0.5%
Top 5 of 15 shown
Web traffic by country
13K monthly visits
across markets
🇮🇳 India90.8%
🇺🇸 United States6.9%
🇵🇭 Philippines1.5%
🇳🇵 Nepal0.8%
Top 4 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Molbio Diagnostics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Molbio Diagnostics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles